Stocksigma LogoStocksigma Logo

Haleos Labs Subsidiary Clears US-FDA Inspection with Zero Observations

US-FDA successfully concluded an inspection at Mahi Drugs Private Limited, a material subsidiary of Haleos Labs Limited, with zero Form 483 observations

Haleos Labs Subsidiary Clears US-FDA Inspection with Zero Observations

Haleos Labs Ltd 路 Others (Uncategorized) 路 18 Sept 2026, 5:22 pm

Haleos Labs Subsidiary Clears US-FDA Inspection with Zero Observations US-FDA successfully concluded an inspection at Mahi Drugs Private Limited, a material subsidiary of Haleos Labs Limited, with zero Form 483 observations. The audit took place from 15th Sep'26 to 18th Sep'26 at its API manufacturing facility in Parawada, Anakapalli, Andhra Pradesh. This matches the clean outcome achieved during the facility's previous US-FDA inspection in Jan'25, reaffirming adherence to regulatory compliance and quality standards.

Original exchange filing (PDF)

More announcements from Haleos Labs Ltd

All Haleos Labs Ltd announcements